Claims
- 1. A vaccine composition comprising an effective amount of a protein encoded by a hybrid DNA molecule comprising a nucleotide sequence from Staphylococcus aureus encoding an isolated protein having fibronectin binding activity, whereby said protein induces immunization by forming antibodies in a mammal against Staphylococcus aureus to provide protection for clinical symptoms to Staphylococcus aureus wherein the hybrid DNA molecule comprises one or more of the nucleotide sequences selected from the group consisting of nucleotides 1-114 of [SEQ ID NO. 2], nucleotides 115-228 of [SEQ ID NO. 2], and nucleotides 229-342 of [SEQ ID NO. 2]: and a pharmaceutical acceptable vaccine carrier therefor.
- 2. A vaccine composition comprising an effective amount of a protein encoded by a hybrid DNA molecule comprising a nucleotide sequence from Staphylococcus aureus encoding an isolated protein having fibronectin binding activity, whereby said protein induces immunization by forming antibodies in a mammal against Staphylococcus aureus to provide protection for clinical symptoms to Staphylococcus aureus, wherein the hybrid DNA molecule comprises the nucleotide sequence set forth in [SEQ ID NO. 4] and a pharmaceutically acceptable vaccine carrier therefor.
- 3. The vaccine composition of claim 2, wherein said mammal is a ruminant.
- 4. The vaccine composition of claim 2, wherein said mammal is a bovine.
- 5. The vaccine composition of claim 2, wherein said mammal is a human.
- 6. A vaccine composition comprising an effective amount of a protein encoded by a plasmid or phage comprising a nucleotide sequence from Staphylococcus aureus encoding an isolated protein having fibronectin binding activity, whereby said sequence of the plasmid or phage comprises [SEQ ID NO. 4] and a pharmaceutically acceptable vaccine carrier therefor.
- 7. A vaccine composition comprising an effective amount of a protein, whereby said protein induces immunization by forming antibodies against Staphylococcus aureus to provide protection for clinical symptoms to Staphylococcus aureus, wherein the protein comprises the amino acid sequence of [SEQ ID NO. 3] and a pharmaceutically acceptable vaccine carrier therefor.
- 8. A vaccine composition comprising an effective amount of a protein encoded by plasmid pFR001 as contained in Escherichia coli strain 259 having the deposit number DSM 4124, said plasmid comprising a nucleotide sequence from Staphylococcus aureus encoding an isolated protein having fibronectin binding activity, whereby said protein induces immunization in a mammal by forming antibodies against Staphylococcus aureus, and a pharmaceutically acceptable vaccine carrier therefor.
Priority Claims (1)
Number |
Date |
Country |
Kind |
8702272 |
Jun 1987 |
SEX |
|
DESCRIPTION
This application is a divisional, of application Ser. No. 08/007,817, filed Jan. 22, 1993, now U.S. Pat. No. 5,320,951, which is a continuation of application Ser. No. 07/201,028, filed Jun. 1, 1988, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5320951 |
Hook et al. |
Jun 1994 |
|
Non-Patent Literature Citations (4)
Entry |
Flock et al., Embo J. 6(8):2351-2357, 1987. |
Ryden et al., J. Biol. Chem. 258(5):3396-3401, 1983. |
Abrahmsen et al., Nucl. Acid. Res. 14: 7487-7500, 1986. |
Lofdahl et al., Pnas, 80, 697-701, Feb. 1983. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
07817 |
Jan 1993 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
201028 |
Jun 1988 |
|